ECCO 15 ESMO 34.

All these patients had failed earlier therapies, either treatment or chemotherapy with Interleukin 2, and also surgery. However, we know that only 10-30 percent of patients will respond to standard chemotherapy, so it is not surprising our patients hadn’t responded, or have responded and the tumor has recurred then. In our study 64 percent of patients have had a partial response, but because we are only treating individuals with the BRAF mutation, we are cutting out about 40 percent of melanoma patients who don’t have this mutation and whom we know will not react to this treatment.That %age, known in the market as ‘the medical-reduction ratio,’ is watched closely by detractors who say insurers take too much money from the operational system in profits. In a statement Monday, the committee said Aetna overstated by $4.9 billion the amount of money it spent on patient care for smaller businesses. As a result, the insurer’s medical-reduction ratio for small businesses was 79 percent, not the 82 percent Aetna primarily reported, it said, drawing focus on a correction that Aetna had made to its filings the other day.’ Aetna corrected its filings ‘proactively’ in an amended survey on Dec. 2. A spokesperson said staff have been alerted to the accounting ‘errors’ and wouldn’t normally do it again the mistake .